{
  "success": true,
  "pagesUsed": [
    3,
    6,
    7,
    14,
    18
  ],
  "modelUsed": "claude-opus-4-5",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "Protocol Summary",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "Protocol Summary",
        "sectionType": {
          "code": "Synopsis",
          "codeSystem": "USDM",
          "decode": "Synopsis"
        },
        "childIds": [
          "nci_1_1",
          "nci_1_2",
          "nci_1_3"
        ]
      },
      {
        "id": "nc_2",
        "name": "Introduction",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "Introduction",
        "sectionType": {
          "code": "Introduction",
          "codeSystem": "USDM",
          "decode": "Introduction"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3"
        ]
      },
      {
        "id": "nc_3",
        "name": "Objectives and Endpoints",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "Objectives and Endpoints",
        "sectionType": {
          "code": "Objectives",
          "codeSystem": "USDM",
          "decode": "Objectives"
        }
      },
      {
        "id": "nc_4",
        "name": "Study Design",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "Study Design",
        "sectionType": {
          "code": "Study Design",
          "codeSystem": "USDM",
          "decode": "Study Design"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4"
        ]
      },
      {
        "id": "nc_5",
        "name": "Study Population",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "Study Population",
        "sectionType": {
          "code": "Study Population",
          "codeSystem": "USDM",
          "decode": "Study Population"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3"
        ]
      },
      {
        "id": "nc_6",
        "name": "Study Assessments and Procedures",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "sectionType": {
          "code": "Assessments",
          "codeSystem": "USDM",
          "decode": "Assessments"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "Biomarker and Noninvasive Test Analyses",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "9",
        "sectionTitle": "Biomarker and Noninvasive Test Analyses",
        "sectionType": {
          "code": "Assessments",
          "codeSystem": "USDM",
          "decode": "Assessments"
        },
        "childIds": [
          "nci_7_1"
        ]
      },
      {
        "id": "nc_8",
        "name": "Administrative and Regulatory Information",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10",
        "sectionTitle": "Administrative and Regulatory Information",
        "sectionType": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2",
          "nci_8_3",
          "nci_8_4",
          "nci_8_5",
          "nci_8_6",
          "nci_8_7"
        ]
      },
      {
        "id": "nc_9",
        "name": "References",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "11",
        "sectionTitle": "References",
        "sectionType": {
          "code": "References",
          "codeSystem": "USDM",
          "decode": "References"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_1_1",
        "name": "Synopsis",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Synopsis"
      },
      {
        "id": "nci_1_2",
        "name": "Schema",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Schema"
      },
      {
        "id": "nci_1_3",
        "name": "Schedule of Activities",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities"
      },
      {
        "id": "nci_2_1",
        "name": "Study Rationale",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Study Rationale"
      },
      {
        "id": "nci_2_2",
        "name": "Background",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Background"
      },
      {
        "id": "nci_2_3",
        "name": "Benefit/Risk Assessment",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3",
        "sectionTitle": "Benefit/Risk Assessment"
      },
      {
        "id": "nci_4_1",
        "name": "Overall Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design"
      },
      {
        "id": "nci_4_2",
        "name": "Scientific Rationale for Study Design",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Scientific Rationale for Study Design"
      },
      {
        "id": "nci_4_3",
        "name": "Justification for Dose",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "Justification for Dose"
      },
      {
        "id": "nci_4_4",
        "name": "End of Study/Study Completion Definition",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.4",
        "sectionTitle": "End of Study/Study Completion Definition"
      },
      {
        "id": "nci_5_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_5_2",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_5_3",
        "name": "Screening",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.4",
        "sectionTitle": "Screening"
      },
      {
        "id": "nci_6_1",
        "name": "FibroScan-Aspartate Aminotransferase Score",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.2.3",
        "sectionTitle": "FibroScan-Aspartate Aminotransferase Score"
      },
      {
        "id": "nci_6_2",
        "name": "HepQuant-SHUNT Disease Severity Index",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.2.10",
        "sectionTitle": "HepQuant-SHUNT Disease Severity Index"
      },
      {
        "id": "nci_7_1",
        "name": "Biomarker and Noninvasive Test Analyses",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.3",
        "sectionTitle": "Biomarker and Noninvasive Test Analyses"
      },
      {
        "id": "nci_8_1",
        "name": "Investigator Responsibilities",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.1.11.2",
        "sectionTitle": "Investigator Responsibilities"
      },
      {
        "id": "nci_8_2",
        "name": "Site Termination or Suspension",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.1.12",
        "sectionTitle": "Site Termination or Suspension"
      },
      {
        "id": "nci_8_3",
        "name": "Clinical Laboratory Tests",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests"
      },
      {
        "id": "nci_8_4",
        "name": "Adverse Events and Serious Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting"
      },
      {
        "id": "nci_8_5",
        "name": "Contraceptive and Barrier Guidance",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive and Barrier Guidance"
      },
      {
        "id": "nci_8_6",
        "name": "Abbreviations and Definitions",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.5",
        "sectionTitle": "Abbreviations and Definitions"
      },
      {
        "id": "nci_8_7",
        "name": "Protocol Amendment History",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.6",
        "sectionTitle": "Protocol Amendment History"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "SARS-CoV-2",
        "expandedText": "severe acute respiratory syndrome coronavirus-2",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "SC",
        "expandedText": "subcutaneously",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "Q4W",
        "expandedText": "every 4 weeks",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AE",
        "expandedText": "Adverse Event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "FAST",
        "expandedText": "FibroScan-aspartate aminotransferase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "NASH",
        "expandedText": "nonalcoholic steatohepatitis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "NAS",
        "expandedText": "NAFLD Activity Score",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CRN",
        "expandedText": "Clinical Research Network",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "Pro-C3",
        "expandedText": "Pro-Collagen type III",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "ELF",
        "expandedText": "Enhanced Liver Fibrosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "HbA1c",
        "expandedText": "Glycated Hemoglobin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "SV1",
        "expandedText": "Screening Visit 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "MRI",
        "expandedText": "Magnetic Resonance Imaging",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "TB",
        "expandedText": "Tuberculosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "F1",
        "expandedText": "Fibrosis Stage 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "F2",
        "expandedText": "Fibrosis Stage 2",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "F3",
        "expandedText": "Fibrosis Stage 3",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "F4",
        "expandedText": "Fibrosis Stage 4",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "F4cc",
        "expandedText": "Fibrosis Stage 4 compensated cirrhosis",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 9,
      "itemCount": 23,
      "abbreviationCount": 19
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment No. 3",
      "versionDate": "18 Sep 2023",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "SARS-CoV-2",
          "expansion": "severe acute respiratory syndrome coronavirus-2"
        },
        {
          "abbreviation": "SC",
          "expansion": "subcutaneously"
        },
        {
          "abbreviation": "Q4W",
          "expansion": "every 4 weeks"
        },
        {
          "abbreviation": "AE",
          "expansion": "Adverse Event"
        },
        {
          "abbreviation": "FAST",
          "expansion": "FibroScan-aspartate aminotransferase"
        },
        {
          "abbreviation": "NASH",
          "expansion": "nonalcoholic steatohepatitis"
        },
        {
          "abbreviation": "NAS",
          "expansion": "NAFLD Activity Score"
        },
        {
          "abbreviation": "CRN",
          "expansion": "Clinical Research Network"
        },
        {
          "abbreviation": "Pro-C3",
          "expansion": "Pro-Collagen type III"
        },
        {
          "abbreviation": "ELF",
          "expansion": "Enhanced Liver Fibrosis"
        },
        {
          "abbreviation": "HbA1c",
          "expansion": "Glycated Hemoglobin"
        },
        {
          "abbreviation": "SV1",
          "expansion": "Screening Visit 1"
        },
        {
          "abbreviation": "MRI",
          "expansion": "Magnetic Resonance Imaging"
        },
        {
          "abbreviation": "TB",
          "expansion": "Tuberculosis"
        },
        {
          "abbreviation": "F1",
          "expansion": "Fibrosis Stage 1"
        },
        {
          "abbreviation": "F2",
          "expansion": "Fibrosis Stage 2"
        },
        {
          "abbreviation": "F3",
          "expansion": "Fibrosis Stage 3"
        },
        {
          "abbreviation": "F4",
          "expansion": "Fibrosis Stage 4"
        },
        {
          "abbreviation": "F4cc",
          "expansion": "Fibrosis Stage 4 compensated cirrhosis"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4",
        "version": "Amendment No. 3",
        "versionDate": "18 Sep 2023"
      },
      "sections": [
        {
          "number": "1",
          "title": "Protocol Summary",
          "type": "Synopsis",
          "subsections": [
            {
              "number": "1.1",
              "title": "Synopsis"
            },
            {
              "number": "1.2",
              "title": "Schema"
            },
            {
              "number": "1.3",
              "title": "Schedule of Activities",
              "subsections": [
                {
                  "number": "1.3.1",
                  "title": "Schedule of Activities: Screening Period"
                },
                {
                  "number": "1.3.2",
                  "title": "Schedule of Activities: Treatment Period, Follow-up, and End of Study"
                }
              ]
            }
          ]
        },
        {
          "number": "2",
          "title": "Introduction",
          "type": "Introduction",
          "subsections": [
            {
              "number": "2.1",
              "title": "Study Rationale"
            },
            {
              "number": "2.2",
              "title": "Background",
              "subsections": [
                {
                  "number": "2.2.1",
                  "title": "Indication and Current Treatment Options"
                },
                {
                  "number": "2.2.2",
                  "title": "Product Background and Mechanism of Action"
                }
              ]
            },
            {
              "number": "2.3",
              "title": "Benefit/Risk Assessment"
            }
          ]
        },
        {
          "number": "3",
          "title": "Objectives and Endpoints",
          "type": "Objectives"
        },
        {
          "number": "4",
          "title": "Study Design",
          "type": "Study Design",
          "subsections": [
            {
              "number": "4.1",
              "title": "Overall Design"
            },
            {
              "number": "4.2",
              "title": "Scientific Rationale for Study Design"
            },
            {
              "number": "4.3",
              "title": "Justification for Dose"
            },
            {
              "number": "4.4",
              "title": "End of Study/Study Completion Definition"
            }
          ]
        },
        {
          "number": "5",
          "title": "Study Population",
          "type": "Study Population",
          "subsections": [
            {
              "number": "5.1",
              "title": "Inclusion Criteria",
              "subsections": [
                {
                  "number": "5.1.1",
                  "title": "Justification of Inclusion Criteria"
                }
              ]
            },
            {
              "number": "5.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "5.4",
              "title": "Screening",
              "subsections": [
                {
                  "number": "5.4.1",
                  "title": "Screen Failures"
                }
              ]
            }
          ]
        },
        {
          "number": "8",
          "title": "Study Assessments and Procedures",
          "type": "Assessments",
          "subsections": [
            {
              "number": "8.2.3",
              "title": "FibroScan-Aspartate Aminotransferase Score"
            },
            {
              "number": "8.2.10",
              "title": "HepQuant-SHUNT Disease Severity Index"
            }
          ]
        },
        {
          "number": "9",
          "title": "Biomarker and Noninvasive Test Analyses",
          "type": "Assessments",
          "subsections": [
            {
              "number": "9.3",
              "title": "Biomarker and Noninvasive Test Analyses"
            }
          ]
        },
        {
          "number": "10",
          "title": "Administrative and Regulatory Information",
          "type": "Other",
          "subsections": [
            {
              "number": "10.1.11.2",
              "title": "Investigator Responsibilities"
            },
            {
              "number": "10.1.12",
              "title": "Site Termination or Suspension",
              "subsections": [
                {
                  "number": "10.1.12.1",
                  "title": "Criteria for Premature Termination or Suspension of Study Sites"
                },
                {
                  "number": "10.1.12.2",
                  "title": "Criteria for Premature Termination or Suspension of the Study"
                },
                {
                  "number": "10.1.12.3",
                  "title": "Procedures for Premature Termination or Suspension of the Study or the Participation of Study Site(s)"
                }
              ]
            },
            {
              "number": "10.2",
              "title": "Clinical Laboratory Tests",
              "subsections": [
                {
                  "number": "10.2.1",
                  "title": "Clinical Laboratory Assessments and Other Safety Assessments"
                }
              ]
            },
            {
              "number": "10.3",
              "title": "Adverse Events and Serious Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
              "subsections": [
                {
                  "number": "10.3.1",
                  "title": "Definition of Adverse Event"
                },
                {
                  "number": "10.3.2",
                  "title": "Definition of Serious Adverse Event"
                },
                {
                  "number": "10.3.3",
                  "title": "Additional Considerations in Identifying and Defining Adverse Events",
                  "subsections": [
                    {
                      "number": "10.3.3.1",
                      "title": "Defining Discrete Adverse Events"
                    },
                    {
                      "number": "10.3.3.2",
                      "title": "Adverse Events of Special Interest"
                    }
                  ]
                },
                {
                  "number": "10.3.4",
                  "title": "Recording and Follow-up of Adverse Events and/or Serious Adverse Events",
                  "subsections": [
                    {
                      "number": "10.3.4.1",
                      "title": "Frequency"
                    },
                    {
                      "number": "10.3.4.2",
                      "title": "Intensity"
                    },
                    {
                      "number": "10.3.4.3",
                      "title": "Causality/Relatedness"
                    },
                    {
                      "number": "10.3.4.4",
                      "title": "Action Taken"
                    },
                    {
                      "number": "10.3.4.5",
                      "title": "Outcome"
                    },
                    {
                      "number": "10.3.4.6",
                      "title": "Follow-up"
                    },
                    {
                      "number": "10.3.4.7",
                      "title": "Reference Safety Information"
                    },
                    {
                      "number": "10.3.4.8",
                      "title": "Unexpected Adverse Events"
                    },
                    {
                      "number": "10.3.4.9",
                      "title": "Pretreatment-emergent Adverse Events"
                    },
                    {
                      "number": "10.3.4.10",
                      "title": "Treatment-emergent Adverse Events"
                    }
                  ]
                },
                {
                  "number": "10.3.5",
                  "title": "Expedited Reporting of Serious Adverse Events and Adverse Events of Special Interest",
                  "subsections": [
                    {
                      "number": "10.3.5.1",
                      "title": "Safety Reporting to Investigators, Institutional Review Boards, and Regulatory Authorities"
                    }
                  ]
                }
              ]
            },
            {
              "number": "10.4",
              "title": "Contraceptive and Barrier Guidance",
              "subsections": [
                {
                  "number": "10.4.1",
                  "title": "Definitions"
                },
                {
                  "number": "10.4.2",
                  "title": "Contraception Guidance",
                  "subsections": [
                    {
                      "number": "10.4.2.1",
                      "title": "Contraceptive Methods for Participants Capable of Producing Viable Ova and/or Becoming Pregnant"
                    },
                    {
                      "number": "10.4.2.2",
                      "title": "Contraceptive Methods for Participants Capable of Producing Viable Sperm"
                    }
                  ]
                },
                {
                  "number": "10.4.3",
                  "title": "Pregnancy"
                }
              ]
            },
            {
              "number": "10.5",
              "title": "Abbreviations and Definitions",
              "subsections": [
                {
                  "number": "10.5.1",
                  "title": "Abbreviations"
                }
              ]
            },
            {
              "number": "10.6",
              "title": "Protocol Amendment History"
            }
          ]
        },
        {
          "number": "11",
          "title": "References",
          "type": "References"
        }
      ]
    }
  }
}